Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2019

01-06-2019 | Hypertension | Editorial

N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?

Author: Richard L. Kravitz, MD, MSPH

Published in: Journal of General Internal Medicine | Issue 6/2019

Login to get access

Excerpt

The use of collective experience to generate expectations for an individual is an example of reference class forecasting.1, 2 Most of what has come to be known as evidence-based medicine is in fact an application of this approach, in which average treatment effects, often derived from parallel group randomized controlled trials, are used to make predictions for individual patients. Unfortunately, while the use of average effects has generally proven superior to anecdote, averages do not always apply. The best reference class for an individual is, of course, him or herself. Therefore, the most direct way to estimate the effects of treatment on an individual is to evaluate an individual’s own experience with two or more forms of treatment (where “treatment” may include active treatment, placebo, or routine care). This approach incorporates what have been referred to as single subject experiments, personalized experiments, or N-of-1 trials. …
Literature
1.
go back to reference Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ. 2018;363:k4245.CrossRefPubMed Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ. 2018;363:k4245.CrossRefPubMed
2.
go back to reference Lovallo D, Kahneman D. Delusions of success. How optimism undermines executives' decisions. Harv Bus Rev. 2003;81(7):56–63, 117.PubMed Lovallo D, Kahneman D. Delusions of success. How optimism undermines executives' decisions. Harv Bus Rev. 2003;81(7):56–63, 117.PubMed
3.
go back to reference Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S21–28. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S21–28.
4.
go back to reference Zucker DR, Ruthazer R, Schmid CH, et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J Rheumatol. 2006;33(10):2069–2077.PubMed Zucker DR, Ruthazer R, Schmid CH, et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J Rheumatol. 2006;33(10):2069–2077.PubMed
5.
go back to reference Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy--randomized trials in individual patients. N Engl J Med. 1986;314(14):889–892.CrossRefPubMed Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy--randomized trials in individual patients. N Engl J Med. 1986;314(14):889–892.CrossRefPubMed
6.
go back to reference Gabler NB, Duan NH, Vohra S, Kravitz RL. N-of-1 Trials in the Medical Literature A Systematic Review. Medical care. 2011;49(8):761–768.CrossRefPubMed Gabler NB, Duan NH, Vohra S, Kravitz RL. N-of-1 Trials in the Medical Literature A Systematic Review. Medical care. 2011;49(8):761–768.CrossRefPubMed
7.
go back to reference Kravitz RL, Schmid CH, Marois M, et al. Effect of Mobile Device-Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain: A Randomized Clinical Trial. JAMA internal medicine. 2018;178(10):1368–1377.CrossRefPubMed Kravitz RL, Schmid CH, Marois M, et al. Effect of Mobile Device-Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain: A Randomized Clinical Trial. JAMA internal medicine. 2018;178(10):1368–1377.CrossRefPubMed
8.
go back to reference Kravitz RL, Paterniti DA, Hay MC, et al. Marketing therapeutic precision: Potential facilitators and barriers to adoption of n-of-1 trials. Contemporary Clinical Trials. 2009;30(5):436–445.CrossRefPubMed Kravitz RL, Paterniti DA, Hay MC, et al. Marketing therapeutic precision: Potential facilitators and barriers to adoption of n-of-1 trials. Contemporary Clinical Trials. 2009;30(5):436–445.CrossRefPubMed
10.
go back to reference Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med. 2010;38(6):600–609.CrossRefPubMed Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med. 2010;38(6):600–609.CrossRefPubMed
11.
go back to reference Materson BJ. Variability in response to antihypertensive drugs. The American journal of medicine. 2007;120(4 Suppl 1):S10–20.CrossRefPubMed Materson BJ. Variability in response to antihypertensive drugs. The American journal of medicine. 2007;120(4 Suppl 1):S10–20.CrossRefPubMed
12.
go back to reference Dhruva SS, Huang C, Spatz ES, et al. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Hypertension. 2017;70(1):94–102.CrossRefPubMed Dhruva SS, Huang C, Spatz ES, et al. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Hypertension. 2017;70(1):94–102.CrossRefPubMed
13.
go back to reference Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What Ever Happened to N-of-1 Trials ? Insiders' Perspectives and a Look to the Future. Milbank Quarterly. 2008;86(4):533–555.CrossRefPubMed Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What Ever Happened to N-of-1 Trials ? Insiders' Perspectives and a Look to the Future. Milbank Quarterly. 2008;86(4):533–555.CrossRefPubMed
Metadata
Title
N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?
Author
Richard L. Kravitz, MD, MSPH
Publication date
01-06-2019
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 6/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-04938-3

Other articles of this Issue 6/2019

Journal of General Internal Medicine 6/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine